eligibility_summary
Include: 18–70 with confirmed advanced NSCLC needing RT for metastases, measurable disease, ECOG 0–1, progressed after 1st‑line (≥2 wks since last therapy), life expectancy ≥3 mo, adequate organ function/labs, infection‑negative, contraception as needed, consent. Exclude: uncontrolled brain mets, need other anticancer therapy, recent steroids/immunotherapy/other trials, major CV disease/uncontrolled HTN, bleeding/thrombosis, active infection/TB, transplant, serious neuro disease, splenectomy, pregnancy, severe allergy, substance abuse, investigator decision.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Interventions and mechanisms: 1) Personalized neoantigen-loaded dendritic cell (DC) vaccine—autologous cellular immunotherapy, patient DCs are pulsed with tumor-specific neoantigen peptides to present via HLA class I/II and prime/expand neoantigen-specific CD8+ cytotoxic and CD4+ helper T cells. 2) PD-1 inhibitor—monoclonal antibody immune checkpoint inhibitor, blocks PD-1 on T cells to prevent PD-L1/PD-L2–mediated inhibition and reverse T-cell exhaustion. 3) Radiotherapy—external-beam radiation, induces immunogenic tumor cell death, releases antigens, upregulates MHC/chemokines, and can activate cGAS-STING/type I IFN, enhancing systemic (abscopal) responses. Targeted cells/pathways: dendritic cells (APCs), effector/memory T cells, PD-1/PD-L1 axis, antigen presentation pathways (HLA I/II), and the irradiated tumor microenvironment. Population: advanced NSCLC post–first-line therapy.